Recent positive Phase 3 INTerpath-001 results for Moderna and Merck’s personalized mRNA vaccine intismeran (mRNA-4157/V940), showing a 42% reduction in melanoma recurrence or death risk when added to Keytruda, represent the primary driver behind elevated trader confidence in a BLA submission by mid-2027. This marks the first late-stage success for an individualized neoantigen therapy outperforming standard immunotherapy alone in resected high-risk melanoma. The companies have confirmed plans to engage regulators promptly and anticipate a 2027 launch, building on earlier Phase 2 durability signals and their established mRNA platform experience. Full data presentation at the upcoming ESMO meeting and any FDA feedback on manufacturing or additional analyses remain key near-term catalysts that could further solidify or modestly adjust timelines amid typical regulatory uncertainties for novel biologics.